IRWD — Ironwood Pharmaceuticals, Inc. stock price, charts and financials

NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·USA

Latest market price

4.42

+0.19+4.49%

Overview Short InterestFilings

IRWDQT90Ironwood Pharmaceuticals, Inc.·NASDAQ

Overview Short InterestFilings

4.42+4.49%

Loading chart...

Screen all →

EVO+1.57%$1.94 AMPH+1.40%$20.22 TLRY+2.20%$4.64 PCRX+1.93%$26.92 AQST+2.43%$3.79 CRON+0.00%$2.83 COLL+0.54%$35.58 KMDA+1.26%$7.23

Snapshot

Index	-	P/E	6.65	EPS (ttm)	0.64	Insider Own	15.71%	Shs Outstand	164.61M	Perf Week	14.02%

Market Cap	696.31M	Forward P/E	3.43	EPS next Y	1.24	Insider Trans	-27.91%	Shs Float	158.48M	Perf Month	2.67%

Enterprise Value	1.07B	PEG	0.00	EPS next Q	-	Inst Own	-	Short Float	10.85%	Perf Quarter	2.42%

Income	102.92M	P/S	1.93	EPS this Y	97.50%	Inst Trans	-	Short Ratio	6.99	Perf Half Y	-12.96%

Sales	361.52M	P/B	-	EPS next Y	4.22%	ROA	23.51%	Short Interest	17.19M	Perf YTD	25.52%

Book/sh	-	P/C	6.16	EPS next 5Y	-27.91%	ROE	-38.88%	52W High	6.04 -26.82%	Perf Year	407.74%

Cash/sh	-	P/FCF	6.21	EPS past 3/5Y	-46.14% -25.65%	ROIC	29.96%	52W Low	0.75 491.61%	Perf 3Y	-60.87%

Dividend Est.	-	EV/EBITDA	5.18	Sales past 3/5Y	-10.36% -5.37%	Gross Margin	99.62%	Volatility	8.23% 5.47%	Perf 5Y	-67.51%

Dividend TTM	-	EV/Sales	2.97	EPS Y/Y TTM	10809.09%	Oper. Margin	55.83%	ATR (14)	0.25	Perf 10Y	-69.44%

Dividend Ex-Date	-	Quick Ratio	1.41	Sales Y/Y TTM	3.13%	Profit Margin	28.26%	RSI (14)	57.43	Recom	2.73

Dividend Gr. 3/5Y	-	Current Ratio	1.41	EPS Q/Q	271.43%	SMA20	4.38%	Beta	0.20	Target Price	3.70

Payout	0.00%	Debt/Eq	-	Sales Q/Q	160.98%	SMA50	10.00%	Rel Volume	1.46	Prev Close	4.23

Employees	100	LT Debt/Eq	-1.51	Earnings	Aug 06	SMA200	15.79%	Avg Volume	2.44M	Price	4.42

IPO Date	Feb 03, 2010	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.70% 15.63%	Net Debt/EBITDA	1.82	Volume	3,572,854	Change	4.49%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Feb-26-26	Reiterated	Jefferies	Hold	$3.70
Jan-05-26	Reiterated	Craig-Hallum	Buy	$3.80 → $5.70
Jan-05-26	Upgrade	Citizens	Market Perform → Market Outperform
Nov-26-25	Reiterated	Craig-Hallum	Buy	$1.70 → $3.80
Apr-15-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-15-25	Downgrade	Jefferies	Buy → Hold
Apr-14-25	Reiterated	Leerink Partners	Market Perform	$5.00 → $1.00
Jan-31-25	Reiterated	Wells Fargo	Overweight	$12 → $7.00
Sep-09-24	Initiated	Leerink	Market Perform	$5.00
Aug-09-24	Reiterated	Wells Fargo	Overweight	$14 → $12

Latest News

Jul-31-26

Jul-31-2609:00AM

Buy The Dip: 2 Top Undervalued Stocks Averaging 394% Forward EPS GrowthSeekingAlpha

Jul-30-26

Jul-30-2609:43AM

Ironwood Pharmaceuticals: One Trial Stands Between Bargain And Bustseekingalpha.com

Jul-15-26

Jul-15-2610:52AM

Here's Why Ironwood Pharmaceuticals (IRWD) is a Strong Momentum Stockzacks.com

Jul-14-26

Jul-14-2607:32AM

Ironwood Pharma Initiates Phase 3 STARS‑2 Trial Of Apraglutide In Short Bowel Syndrome With Intestinal FailureBenzinga

07:30AM

Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patientsbusinesswire.com

Jul-08-26

Jul-08-2609:26AM

4 Defensive Stocks to Take Refuge in as Tech Sell-off Continueszacks.com

Jul-07-26

Jul-07-2609:00PM

Get insights into the top gainers and losers of Tuesday's after-hours session.ChartMill

Company

Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	362	296	351	443	411	414	390	428	347
Cost of Goods Sold Incl. D&A	0	0	8	6	1	70	3	135	33
Gross Profit	361	296	344	437	409	343	386	293	314
Selling, General and Administrative Excl. Other	70	82	0	0	116	0	140	0	241
Research and Development	88	95	111	116	44	70	88	122	167
Other Operating Expense	1	0	140	1,266	-1	41	15	51	8
Operating Income	203	119	93	-945	250	232	143	120	-239
Interest Expense	33	33	33	22	8	31	29	37	38
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	4	-16	5	19	10	0	-5	-25	-6
Net Income Before Taxes	171	70	65	-948	252	201	109	59	-282
Income Taxes	69	46	64	83	77	-328	3	0	-6
Consolidated Net Income	103	24	1	-1,002	175	528	106	22	-282
Net Income From Continuing Operations	103	24	1	-1,032	175	528	106	59	-194
Net Income	103	24	1	-1,002	175	528	106	22	-282
EPS (Recurring)	0.64	0.15	0.01	-6.45	1.13	3.26	0.67	-0.10	-1.85
EPS (Basic, Before Extraordinaries)	0.64	0.15	0.01	-6.45	1.13	3.26	0.67	-0.10	-1.85
EPS (Diluted)	0.60	0.15	0.01	-6.45	0.96	3.21	0.66	-0.10	-1.85
EBITDA	208	105	98	197	261	234	142	129	-144
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	7.37	22.47	805.45	—	12.91	3.63	17.26	—	—
Price To Sales Ratio	1.99	1.84	2.01	4.00	4.64	4.56	4.64	4.85	4.57
Gross Margin	99.72	100.00	98.01	98.65	99.51	82.85	98.97	68.46	90.49
Operating Margin	56.08	40.20	26.50	-213.32	60.83	56.04	36.67	28.04	-68.88
Net Margin	28.45	8.11	0.28	-226.19	42.58	127.54	27.18	5.14	-81.27
Shares Outstanding	163	162	159	155	154	162	159	156	153
Market Capitalization	720	546	704	1,773	1,908	1,889	1,811	2,076	1,585
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Silver Ronald	PFO & PAO	Jul 07 '26	Sale	4.52	127,890	578,063	313,680	Jul 09
McHugh Julie	Director	Jun 16 '26	Sale	3.73	21,571	80,460	250,749	Jun 17
DENNER ALEXANDER J	Director	Mar 17 '26	Sale	3.05	6,730,800	20,530,448	9,188,635	Mar 17
Gaskins Tammi L	Chief Commercial Officer	Feb 24 '26	Sale	3.66	11,239	41,135	213,738	Feb 25
John Minardo	Chief Legal Officer	Feb 24 '26	Sale	3.66	19,053	69,734	363,886	Feb 25
Shetzline Michael	SVP, CMO, Head-Res&Drug	Feb 24 '26	Sale	3.66	17,012	62,264	521,425	Feb 25
MCCOURT Thomas A	Chief Executive Officer	Feb 24 '26	Sale	3.66	103,526	378,905	1,489,002	Feb 25
Martini Gregory S.	Chief Financial Officer	Feb 24 '26	Sale	3.66	11,457	41,933	160,601	Feb 25
Silver Ronald	Principal Accounting Officer	Feb 24 '26	Sale	3.66	12,621	46,193	252,636	Feb 25
MCCOURT Thomas A	Chief Executive Officer	Feb 23 '26	Sale	3.81	94,757	361,024	1,592,528	Feb 25
Martini Gregory S.	Chief Financial Officer	Feb 23 '26	Sale	3.81	10,487	39,955	172,058	Feb 25
Silver Ronald	Principal Accounting Officer	Feb 23 '26	Sale	3.81	11,552	44,013	265,257	Feb 25
Shetzline Michael	SVP, CMO, Head-Res&Drug	Feb 23 '26	Sale	3.81	15,570	59,322	538,437	Feb 25
Gaskins Tammi L	Chief Commercial Officer	Feb 23 '26	Sale	3.81	10,287	39,193	224,977	Feb 25
John Minardo	Chief Legal Officer	Feb 23 '26	Sale	3.81	17,439	66,443	382,939	Feb 25

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.